Auranofin Repurposing for Lung and Pancreatic Cancer: Low CA12 Expression as a Marker of Sensitivity in Patient-Derived Organoids, with Potentiated Efficacy by AKT Inhibition

Our investigation employed a comprehensive drug screening of Auranofin in combination with eleven anticancer agents in cancerous PDAC and NSCLC patient-derived organoids, and non-cancerous pulmonary organoids.